NOVIOSENSE
Nijmegen
About NOVIOSENSE
Their vision is to free diabetics from the painful finger prick and throughout this leverage for their shareholders the significant market potential that such a non-invasive glucose monitor could achieve. Diabetes is a global problem; almost 600m patients will be suffering from this disease by 2032. The majority of severe diabetics undergo a painful reminder of their disease multiple times a day by means of drawing blood to measure their glucose levels. I strongly believe that we can free the diabetic from this antiquated and painful reminder, which is why NovioSense set out in 2012 to reinvent the way we measure glucose. We believe that by reimagining the finger strip technology into a new form factor our non-invasive device will allow patients to monitor glucose levels on demand not only non-invasively but also unobtrusively. We have discovered that tears are a unique source of biomarkers with excellent prediction of blood biomarker levels. Armed with this knowledge we have developed a non-invasive sensor capable of detecting trace levels of glucose in tears and accurately extrapolating these values back to blood glucose levels.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $2.0M
- Funding stage: Late Stage Venture
- Last round: Series D (Oct 2016)
- Website: noviosense.com
- Phone: +310247114015
Industries & Categories
Medical Device
Social Profiles
Canonical: https://fsome.com/organization/noviosense-2450249 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.